Cognition Therapeutics, Inc. - Special Call Transcript
Good morning, everybody. Thank you for joining us on our age-related macular degeneration symposium today. My name is Lisa Ricciardi. I'm the President and CEO of Cognition Therapeutics. And on behalf of our team and our advisers, I welcome you to this discussion.
Today, we'll be reviewing our data presented at ARVO last month. We'll also be reviewing our rationale for why we are choosing to advance in the dry age-related macular degeneration. All of this will be discussed against the backdrop of current therapies and new insights relative to age-related macular degeneration.
Please note, as a public company, we'd like to point you to our forward-looking statements. You're welcome to review this on our website as well.
I apologize, there is a delay in advancing the slides.
So let me turn briefly to who is Cognition Therapeutics. As many of you know, this is a company that started as a research-based [MC] in Pittsburgh a number of years ago. The company was founded based on the scientific
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |